P.V. Bulychkin, S.I. Tkachev, V.B. Matveev, A.V. Khachaturyan, A.A. Kufelkina
N.N. Blokhin National Medical Research Center of Oncology, Moscow
Bulychkin Petr V. ― Cand. of Sci. (Med.), Senior Researcher at the Radiotherapy Department of the Research Institute of Clinical Oncology of the N.N. Blokhin National Medical Research Center of Oncology
24 Kashirskoe highway, Moscow, 115478, Russian Federation, tel. +7-926-313-22-07, e-mail: petrbulychkin@gmail.com, ORCID ID: 0000-0003-3947-1267, RSCI: 442908455
Abstract
Introduction. Salvage radiation therapy (SRT) is the main treatment option for patients with biochemical and/or locoregional recurrence of prostate cancer (PCa) without signs of distant metastasis after radical prostatectomy (RP). This study demonstrates the long-term 5-year and 10-year results of SRT in this category of patients using modern technologies and radiotherapy techniques.
Purpose ― improving the effectiveness of SRT in patients with biochemical recurrence of prostate cancer after RP.
Material and methods. A retrospective and prospective single-center cohort study included patients with biochemical recurrence of prostate cancer after RP. All patients underwent SRT or combined therapy (SRT and hormonal therapy) in the mode of classical or hypofractionation of the dose using modern technologies. The primary endpoint is 5- and 10-year progression-free survival (PFS).
Results. From 2008 to 2023, SRT was performed in 531 patients with biochemical recurrence of prostate cancer after RP. The median follow-up was 76 (3-124) months. The 5-year and 10-year PFS were 93% and 82%, respectively.
Conclusion. The results of this study show that SRT is a radical method of treating patients with locoregional recurrence of prostate cancer after RP with high long-term oncological results
Key words: prostate cancer, salvage radiation therapy, biochemical recurrence, local recurrence, PSA.